Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials

By afschroeder • November 29, 2025

Guttman-Yassky E, Kabashima K, Worm M, Luna PC, Hong HC, Chovatiya R, Bernstein JA, Kern JS, Ehst BD, Magnolo N, Herranz-Pinto P, Stein Gold L, Sofen H, Pink AE, Esfandiari E, Arai T, Yang Y, Shi R, Barragan C, Kricorian G, Schwartz-Sagi L, Bissonnette R. Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials. Lancet. 2025 Nov 25:S0140-6736(25)01865-3. doi: 10.1016/S0140-6736(25)01865-3. Epub ahead of print. PMID: 41314226.

Tags: Dermatology, Olive View DoM, Publications

Development of a Core Outcome Domain Set for Facial Aging

Dirr MA, Ahmed A, Schlessinger DI, Lazaro-Camp V, Smith S, Gullapalli T, Dragovic D, Chang J, Zhang E, Alam M; Facial Aging Core Outcome Domain[...]

Cutibacterium acnes induce T cell extracellular traps with distinct proteome programs

To TT, Deng M, Andrade PR, Nguyen NPN, Brewer GM, Hu C, Agak GW. Cutibacterium acnes induce T cell extracellular traps with distinct proteome programs.[...]

Patient Preferences for Treatment Attributes in Moderate to Severe Chronic Hand Eczema: A Discrete Choice Experiment

Armstrong AW, Bin Sawad A, Hazra NC, Balu S, Maslin D, Libchaber B, Huang R, Gauthier-Loiselle M, Guerin A. Patient Preferences for Treatment Attributes in[...]